{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:11:13Z","timestamp":1789578673835,"version":"build-2803163510"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhengzhou City Medical and Health Science and Technology Innovation Guidance Program Project","award":["2025YLZDJH158"],"award-info":[{"award-number":["2025YLZDJH158"]}]},{"name":"Scientific Research Project of Women and Infants Hospital of Zhengzhou, China","award":["YNKY202409"],"award-info":[{"award-number":["YNKY202409"]}]},{"name":"China Medical Education Association Gathering Talents Scientific Research Project","award":["CMEAPC2024030"],"award-info":[{"award-number":["CMEAPC2024030"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Suicide adverse events are a serious concern with zopiclone and eszopiclone. This study assessed the risk of such events by mining data from the FAERS, JADER, and CVARD databases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The analysis included reports from Q1 2004 to Q4 2024 for FAERS, April 2004 to December 2024 for JADER, and January 1991 to December 2024 for CVARD. The risk was analyzed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Information Component (IC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 361 reports of suicide adverse events linked to zopiclone and eszopiclone were included (FAERS: 120; JADER: 44; CVARD: 197). These events encompassed completed suicide, suicide attempt, suicidal ideation, suicidal behavior, self-injurious ideation, and intentional self-injury. Suicide attempt was consistently detected as a positive signal by all three methods across all databases and classified as a medium clinical priority.Multivariable logistic regression analysis from FAERS data indicated that males had an independently increased risk of suicide associated with these drugs [OR (95% CI): 14.70 (2.64\u2013274.75), p\u2009=\u20090.012]. Most suicide-related events (60.0%) occurred within 0\u2013180 days after taking medication. based on FAERS data. Survival analysis showed no significant gender difference in time to suicide onset (p\u2009=\u20090.15). The hazard rate remained constant over time (Weibull shape \u03b2\u2009=\u20090.80). Death was the outcome in 50.0% of cases following suicide onset. The average reported doses for zopiclone (262.5\u2009mg) and eszopiclone (25.6\u2009mg) significantly exceeded maximum recommended dosages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings align with published reports and clinical observations, highlighting the need for further clinical trials to investigate suicide associated with zopiclone and eszopiclone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0340357","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:32:25Z","timestamp":1767897145000},"page":"e0340357","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Suicide adverse events associated with zopiclone and eszopiclone: A pharmacovigilance analysis based on FAERS, JADER and CVARD"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2899-771X","authenticated-orcid":true,"given":"Yinpeng","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1719-8943","authenticated-orcid":true,"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"1","key":"pone.0340357.ref001","first-page":"29","article-title":"Insomnia: Pharmacologic therapy","volume":"96","author":"M Eric","year":"2017","journal-title":"American Family Physician"},{"issue":"14","key":"pone.0340357.ref002","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1111\/bph.13142","article-title":"Zolpidem and eszopiclone prime \u03b11\u03b22\u03b32 GABAA receptors for longer duration of activity","volume":"172","author":"CL Dixon","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"1","key":"pone.0340357.ref003","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cger.2007.08.009","article-title":"Pharmacotherapy for insomnia","volume":"24","author":"SH Tariq","year":"2008","journal-title":"Clin Geriatr Med"},{"issue":"4","key":"pone.0340357.ref004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinthera.2006.04.014","article-title":"Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia","volume":"28","author":"J Najib","year":"2006","journal-title":"Clin Ther"},{"issue":"03","key":"pone.0340357.ref005","first-page":"169","article-title":"Sleep risk factors of suicidal behavior during depressive episode","volume":"33","author":"J Liu","year":"2023","journal-title":"Journal of Clinical Psychiatry"},{"issue":"1","key":"pone.0340357.ref006","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1176\/appi.ajp.2016.16030336","article-title":"Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA","volume":"174","author":"WV McCall","year":"2017","journal-title":"Am J Psychiatry"},{"key":"pone.0340357.ref007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-227X-10-13","article-title":"Fatal poisonings in Oslo: a one-year observational study","volume":"10","author":"MA Bjornaas","year":"2010","journal-title":"BMC Emerg Med"},{"issue":"3","key":"pone.0340357.ref008","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40264-019-00885-4","article-title":"Fatal toxicity indices for medicine-related deaths in New Zealand, 2008-2013","volume":"43","author":"JS Fountain","year":"2020","journal-title":"Drug Saf"},{"issue":"10","key":"pone.0340357.ref009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0960327107084045","article-title":"Eszopiclone ingestions reported to Texas poison control centers, 2005 2006","volume":"26","author":"MB Forrester","year":"2007","journal-title":"Hum Exp Toxicol"},{"key":"pone.0340357.ref010","first-page":"44","article-title":"Eszopiclone-induced parasomnia with suicide attempt: A case report","volume":"13","author":"JG Pennington","year":"2016","journal-title":"Innov Clin Neurosci"},{"issue":"6","key":"pone.0340357.ref011","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/ph15060675","article-title":"Pharmacovigilance signals of the opioid epidemic over 10 years: data mining methods in the analysis of pharmacovigilance datasets collecting adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS)","volume":"15","author":"S Chiappini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"pone.0340357.ref012","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.21873\/invivo.13586","article-title":"Risk and Time-to-onset of acute kidney injury with vancomycin plus piperacillin-tazobactam combination: analysis using JADER","volume":"38","author":"N Ide","year":"2024","journal-title":"In Vivo"},{"issue":"1","key":"pone.0340357.ref013","doi-asserted-by":"crossref","first-page":"40","DOI":"10.12927\/hcq.2020.26140","article-title":"Adverse Drug Reactions in Canada (2009-2018): Insights from the canada vigilance database","volume":"23","author":"TS Maity","year":"2020","journal-title":"Healthc Q"},{"issue":"6","key":"pone.0340357.ref014","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"T Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"issue":"5","key":"pone.0340357.ref015","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13331","article-title":"Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system","volume":"73","author":"L Meng","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"1","key":"pone.0340357.ref016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0962280211403602","article-title":"Disproportionality methods for pharmacovigilance in longitudinal observational databases","volume":"22","author":"I Zorych","year":"2013","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"pone.0340357.ref017","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"A Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pone.0340357.ref018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"R B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"issue":"04","key":"pone.0340357.ref019","first-page":"1394","article-title":"Study on adverse drug reaction signal detection and automatic warning technology based on BCPNN method","volume":"26","author":"W Chen","year":"2009","journal-title":"Applied Research of Computers"},{"issue":"6","key":"pone.0340357.ref020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"SJ Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"pone.0340357.ref021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"pone.0340357.ref022","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"pone.0340357.ref023","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11523-024-01058-9","article-title":"Emerging toxicities of antibody-drug conjugates for breast cancer: clinical prioritization of adverse events from the FDA adverse event reporting system","volume":"19","author":"S Cecco","year":"2024","journal-title":"Target Oncol"},{"issue":"7","key":"pone.0340357.ref024","first-page":"2121","article-title":"Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives","volume":"61","author":"LP Longo","year":"2000","journal-title":"Am Fam Physician"},{"issue":"9","key":"pone.0340357.ref025","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1016\/j.neubiorev.2011.01.003","article-title":"Affective neuroscientific and neuropsychoanalytic approaches to two intractable psychiatric problems: why depression feels so bad and what addicts really want","volume":"35","author":"MR Zellner","year":"2011","journal-title":"Neurosci Biobehav Rev"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T18:32:31Z","timestamp":1767897151000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0340357"}},"subtitle":[],"editor":[{"given":"James M","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0340357","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}